Avastin and new treatments for AMD: where are we?
Freeman
William R
WR
Falkenstein
Iryna
I
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D008268:Macular Degeneration / Q000150:complications / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab